$LQDA

KIRSCH ARTHUR S sold $1.7M of LQDA (indirect holdings)

KIRSCH ARTHUR S sold 30,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $57.71 ($54.80–$60.22, $1.73M total) across 3 trades over 2026-06-01 to 2026-06-03.

Original reporting
SEC EDGAR · KIRSCH ARTHUR S
Published Jun 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest information is the disclosed sale size, price range, and post-sale share count (0), which may influence short-term sentiment but does not change operating outlook based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or correlate with broader news, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales can be driven by diversification, tax, or pre-existing personal liquidity needs; the article provides no rationale, so the trading signal should be treated as sentiment-only.

Relevance 6/10Novelty 3/10Timing: filed June 3, 2026, covering sales from June 1 to June 3

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by a director via indirect holdings.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp (LQDA) disclosed an insider Form 4 showing director Kirs ch Arthur S sold 30,000 shares indirectly for about $1.73M.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

Form 4 details a completed open-market sale across three trades at $54.80 to $60.22, with holdings after transaction at 0 shares. The disclosure does not include new company fundamentals, guidance, or regulatory/clinical developments.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Because the director ended with 0 shares and there is no stated 10b5-1 plan, some traders may interpret it as stronger-than-usual negative signaling, even if the filing is still typically low-signal.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure (LQDA).

  • Kirs ch Arthur S

    Director reporting an indirect open-market sale of 30,000 shares across three trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.